LA Times -- Mannkind Corp., the Valencia biotech firm, announced that it would lay off 41% of its workforce and focus on receiving regulatory approval for its long-delayed insulin inhaler being developed for people with diabetes.
LA Times -- Mannkind Corp., the Valencia biotech firm, announced that it would lay off 41% of its workforce and focus on receiving regulatory approval for its long-delayed insulin inhaler being developed for people with diabetes.
